Sierra Oncology, Inc. - Common Stock (NQ:SRRA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 30, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sierra Oncology, Inc. - Common Stock

< Previous 1 2 3 Next >

Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 18, 2022

From Sierra Oncology

Via Business Wire

Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 04, 2022

From Sierra Oncology

Via Business Wire

Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 03, 2022

From Sierra Oncology

Via Business Wire

Sierra Oncology Raises $135M Via Equity To Fund Lead Program Development ↗

January 27, 2022

Sierra Oncology Inc (NASDAQ: SRRA) has priced its underwritten public offering of 4.07 million shares at $27 per share and the pre-funded warrants at $26.999 per pre-funded warrant.

Via Benzinga

Sierra Oncology to Participate in Guggenheim Oncology Conference

February 03, 2022

From Sierra Oncology

Via Business Wire

Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities

January 31, 2022

From Sierra Oncology

Via Business Wire

Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference

January 27, 2022

From Sierra Oncology

Via Business Wire

R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments

January 27, 2022

Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,...

Via FinancialNewsMedia

Topics Death Intellectual Property

41 Biggest Movers From Yesterday ↗

January 27, 2022

Gainers Ebang International Holdings Inc. (NASDAQ: EBON) shares gained 35.4% to settle at $1.09 on Wednesday as investors weighed the Federal Reserve Reserve decision to leave...

Via Benzinga

Sierra Oncology Announces Pricing of Upsized Public Offering of Securities

January 26, 2022

From Sierra Oncology

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 26, 2022

Gainers Reneo Pharmaceuticals (NASDAQ:RPHM

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

January 26, 2022

Gainers Rani Therapeutics Hldgs (NASDAQ:RANI

Via Benzinga

32 Stocks Moving In Wednesday's Mid-Day Session ↗

January 26, 2022

Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 32% to $0.7262 after the company announced a share buyback of up to 100 million shares of common stock at $1 per share...

Via Benzinga

The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data ↗

January 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

18 Stocks Moving in Wednesday's Pre-Market Session ↗

January 26, 2022

Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.1% to $0.23 in pre-market trading after gaining around 4% on Tuesday. Barfresh Food Group, Inc. (NASDAQ: BRFH) shares rose 31.7% to $...

Via Benzinga

51 Biggest Movers From Yesterday ↗

January 26, 2022

Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients...

Via Benzinga

Sierra Oncology Announces Proposed Public Offering of Common Stock

January 25, 2022

From Sierra Oncology

Via Business Wire

Mid-Afternoon Market Update: Dow Turns Higher; General Electric Shares Slide ↗

January 25, 2022

Toward the end of trading Tuesday, the Dow traded up 0.12% to 34,405.65 while the NASDAQ fell 1.19% to 13,690.05. The S&P also fell, dropping, 0.57% to 4,384.81. The U.S...

Via Benzinga

Mid-Day Market Update: Nasdaq Tumbles 300 Points; Sierra Oncology Shares Jump ↗

January 25, 2022

Midway through trading Tuesday, the Dow traded down 1.15% to 33,968.17 while the NASDAQ fell 2.20% to 13,549.98. The S&P also fell, dropping, 1.68% to 4,336.24. The U.S. has...

Via Benzinga

28 Stocks Moving In Tuesday's Mid-Day Session ↗

January 25, 2022

Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares jumped 47.8% to $22.93 after the company unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic,...

Via Benzinga

Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way ↗

January 25, 2022

Sierra Oncology spent just $3 million up front to acquire momelotinib.

Via Investor's Business Daily

Sierra Oncology Secures Debt Facility Of Up To $125M With Oxford Finance To Support Momelotinib Development ↗

January 25, 2022

Sierra Oncology Inc (NASDAQ: SRRA) has entered into a term loan agreement with Oxford Finance LLC to support the commercial preparation and potential...

Via Benzinga

Sierra Oncology Shares Rally As Bone Marrow Cancer Candidate Hits Primary Goal ↗

January 25, 2022

Sierra Oncology Inc (NASDAQ: SRRA) unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic, anemic, and previously treated with an FDA-...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 25, 2022

Gainers Sierra Oncology (NASDAQ:SRRA) stock rose 45.6% to $22.58 during Tuesday's pre-market session. The market value of their outstanding shares is at $339.9 million...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data ↗

January 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,...

Via Benzinga

Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib

January 25, 2022

From Sierra Oncology

Via Business Wire

Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis

January 25, 2022

From Sierra Oncology

Via Business Wire

Momelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis Patients

January 19, 2022

From Sierra Oncology

Via Business Wire

Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis

January 18, 2022

From Sierra Oncology

Via Business Wire

Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

January 07, 2022

From Sierra Oncology

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.